What is it about?
This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects.
Featured Image
Why is it important?
This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects.
Perspectives
This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects.
Mr. Sunil Shrestha
Read the Original
This page is a summary of: Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?, F1000Research, January 2020, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.21962.1.
You can read the full text:
Contributors
The following have contributed to this page
